Abstract
With advances in medical care, the predicted median survival of individuals with sickle cell disease has increased dramatically over the last several decades. As a result, an increasing number of individuals born with sickle cell disease are surviving well into adulthood, thus making it likely that many primary care providers will see patients with this condition in their adult medical practices. This chapter provides an overview of the common therapeutic interventions employed in the management of sickle cell disease as well as clinical considerations for reproductive health and genetic counseling. The recognition and management of chronic comorbid conditions often seen in adults with sickle cell disease are also discussed. Further, the chapter will highlight strategies in the assessment and management of chronic pain in young adults.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Hamideh D, Alvarez O. Sickle cell disease related mortality in the United States (1999–2009). Pediatr Blood Cancer. 2013;60(9):1482–6.
Kanter J, Kruse-Jarres R. Management of sickle cell disease from childhood through adulthood. Blood Rev. 2013;27(6):279–87.
Hemker BG, Brousseau DC, Yan K, Hoffmann RG, Panepinto JA. When children with sickle-cell disease become adults: lack of outpatient care leads to increased use of the emergency department. Am J Hematol. 2011;86(10):863–5.
Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Duh MS. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs. Pediatr Blood Cancer. 2013;60(5):828–35.
Helton KJ, Adams RJ, Kesler KL, Lockhart A, Aygun B, Driscoll C, et al. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood. 2014;124(6):891–8.
Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317–22.
Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289(13):1645–51.
Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010;85(6):403–8.
Evidence Based Management of Sickle Cell Disease: Expert Report 2014. Expert Panel Report, 2014. US Department of Health and Human Services, National Institutes of Health. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/sites/www.nhlbi.nih.gov/files/sickle-cell-disease-report.pdf.
Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387(10019):661–70. doi:10.1016/S0140-6736(15)01041-7. Epub 2015 Dec 6.
Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033–48. https://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines.
Walsh KE, Cutrona SL, Kavanagh PL, Crosby LE, Malone C, Lobner K, et al. Medication adherence among pediatric patients with sickle cell disease: a systematic review. Pediatrics. 2014;134(6):1175–83.
Mainous AG, Tanner RJ, Harle CA, Baker R, Shokar NK, Hulihan MM. Attitudes toward management of sickle cell disease and its complications: a national survey of academic family physicians. Anemia. 2015;2015:853835.
National Institute for Children’s Health Quality. SCDTDP Congressional Report: Recommendations for improving care for people with sickle cell disease. 2014. http://sicklecell.nichq.org/resources/scdtdp-congressional-report.
Brousseau DC, Panepinto AJ, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: national and state estimates. Am J Hematol. 2010;85(1):77–8.
Hassell KL. Population estimates of sickle cell disease in the U.S. American. J Prevent Med. 2010;38(4, Supplement):S512–21.
Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease—life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639–44.
Therrell BLHWH. National evaluation of US newborn screening system components. Ment Retard Dev Disabil Res Rev 2006;12(4):236–45.
Powars DR, Chan L, Hiti AL, Ramicone E, Johnson C. Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. Medicine. 2005;84(6):363–376.
Brown S-E, Weisberg DF, Balf-Soran G, Sledge WH. Sickle cell disease patients with and without extremely high hospital use: pain, opioids, and coping. J Pain Symptom Manag. 2015;49(3):539–47.
Matthie N, Jenerette C, McMillan S. Role of self-care in sickle cell disease. Pain Manag Nurs. 2015;16(3):257–66.
Molter BL, Abrahamson K. Self-efficacy, transition, and patient outcomes in the sickle cell disease population. Pain Manag Nurs. 2015;16(3):418–24.
Crosby L, Quinn C, Kalinyak K. A biopsychosocial model for the management of patients with sickle-cell disease transitioning to adult medical care. Adv Ther. 2015;32(4):293–305.
Klings ES, Machado RF, Barst RJ, Morris CR, Mubarak KK, Gordeuk VR, et al. An official american thoracic society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med. 2014;189(6):727–40.
Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP. MMWR Morb Mortal Wkly Rep. 2012;61(40):816–9.
Ataga KI, Derebail VK, Archer DR. The glomerulopathy of sickle cell disease. Am J Hematol. 2014;89(9):907–14.
Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5–11.
Lee MT, Piomelli S, Granger S, Miller ST, Harkness S, Brambilla DJ, et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood. 2006;108(3):847–52.
Ware RE, Helms RW. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood. 2012;119(17):3925–32.
Elagouz M, Jyothi S, Gupta B, Sivaprasad S. Sickle cell disease and the eye: old and new concepts. Surv Ophthalmol. 2010;55(4):359–77.
Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, et al. prophylaxis with oral penicillin in children with sickle cell anemia. N Engl J Med. 1986;314(25):1593–9.
Rogers DT, Molokie R. Sickle cell disease in pregnancy. Obstet Gynecol Clin North Am. 2010;37(2):223–37.
Goodman J, McGrath P. The epidemiology of pain in children and adolescents: a review. Pain. 1991;46(1758709):247–64.
Perquin C, Hazebroek-Kampschreur AA, Hunfeld JA, Bohnen AM, van Suijlekom-Smit LW, Passchier J, et al. Pain in children and adolescents: a common experience. Pain. 2000;87(1):51–8.
National Center for Health Statistics. Health, United States, 2006, With chartbook on trends in the health of Americans with special feature on pain. Hyattsville, MD; 2006:68–87.
Keogh E, Eccleston C. Sex differences in adolescent chronic pain and pain-related coping. Pain. 2006;123(3):275–84.
Roth-Isigkeit A, Thyen U, Raspe HH, Stöven H, Schmucker P. Reports of pain among German children and adolescents: an epidemiological study. Acta Paediatr. 2004;93(2):258–63.
Roth-Isigkeit A, Thyen U, Stöven H, Schwarzenberger J, Schmucker P. Pain among children and adolescents: restrictions in daily living and triggering factors. Pediatrics. 2005;115(4):e152–62.
Palermo TM, Kiska R. Subjective sleep disturbances in adolescents with chronic pain: relationship to daily functioning and quality of life. J Pain. 2005;6(3):201–7.
Jordan AL, Eccleston C, Osborn M. Being a parent of the adolescent with complex chronic pain: an interpretative phenomenological analysis. Eur J Pain. 2007;11(1):49–56.
Eccleston C, Crombez G, Scotford A, Clinch J, Connell H. Adolescent chronic pain: patterns and predictors of emotional distress in adolescents with chronic pain and their parents. Pain. 2004;108(3):221–9.
Fortuna R, Robbins B, Caiola E, Joynt M, Halterman J. Prescribing of controlled medications to adolescents and young adults in the united states. Pediatrics. 2010;126(6):1108–16.
Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Phys. 2008;11(2 Suppl):S63–88.
Johnston L, O’Malley P, Bachman J, Schulenberg J. Monitoring the future national survey results on drug use, 1975–2008: volume 1, Secondary school students. Bethesda, MD: National Institute on Drug Abuse; 2009.
Results from the 2008 National Survey on Drug Use and Health: National Findings. Rockville, MD; 2009:HHS SMA 09-4434.
Mccabe S, West B, Teter C, Boyd C. Medical and non-medical uses of prescription opioids among high school seniors in the United States. Arch Pediatr Adolesc Med. 2012;166(9):797–802.
Fortuna RJ, Robbins BW, Halterman JS. Ambulatory care among young adults in the United States. Ann Intern Med. 2009;151(6):379–85.
Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–30.e22.
Stinson J, Kavanagh T, Yamada J, Gill N, Stevens B. Systematic review of the psychometric properties, interpretability and feasibility of self-report pain intensity measures for use in clinical trials in children and adolescents. Pain. 2006;142:143–57.
Hicks CL, von Baeyer CL, Spafford PA, van Korlaar I, Goodenough B. The Faces Pain Scale-Revised: toward a common metric in pediatric pain measurement. Pain. 2001;93(2):173–83.
Thompson K, Varni J, Hanson V. Comprehensive assessment of pain in juvenile rheumatoid arthritis: an empirical model. J Pediatr Psychol. 1987;12(2):241–55.
Cohen LL, Lemanek K, Blount RL, Dahlquist LM, Lim CS, Palermo TM, et al. Evidence-based assessment of pediatric pain. J Pediatr Psychol. 2008;33(9):939–55.
Eccleston C, Jordan AL, Crombez G. The impact of chronic pain on adolescents: a review of previously used measures. J Pediatr Psychol. 2006;31(7):684–97.
Eccleston C, Jordan A, McCracken L, Sleed M, Connell H, Clinch J. The Bath Adolescent Pain Questionnaire (BAPQ): development and preliminary psychometric evaluation of an instrument to assess the impact of chronic pain on adolescents. Pain. 2005;118:263–70.
Teri L. The use of the Beck Depression inventory with adolescents. J Abnorm Child Psychol. 1982;10(1):277–84.
Roberts R, Andrews J, Lewinsohn P, Hops H. Assessment of depression in adolescents using the Center for Epidemiologic Studies Depression Scale. Psychol Assess. 1990;2(2):122–8.
Richardson LP, Russo JE, Katon W, McCarty CA, DeVries A, Edlund MJ, et al. Mental health disorders and long-term opioid use among adolescents and young adults with chronic pain. J Adolesc Health. 2012;50(6):553–8.
Webster L, Webster R. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432–42.
Jones T, Lookatch S, Moore T. Validation of a new risk assessment tool: the Brief Risk Questionnaire. J Opioid Manag. 2015;11(2):171–83.
Eccleston C, Clinch J. Adolescent chronic pain and disability: a review of the current evidence in assessment and treatment. Paediatr Child Health. 2007;12(2):117–20.
Bodenheimer T. Transforming practice. N Engl J Med. 2008;359(20):2086–9.
Stinson J, Lalloo C, Harris L, Isaac L, Campbell F, Brown S, et al. iCanCope with Pain™: user-centred design of a web- and mobile-based self-management program for youth with chronic pain based on identified health care needs. Pain Res Manag. 2014;19(5):257–65.
Stinson JN, Mcgrath PJ, Hodnett ED, Feldman BM, Duffy CM, Huber AM, et al. An Internet-based self-management program with telephone support for adolescents with arthritis: a pilot randomized controlled trial. J Rheumatol. 2010;37(9):1944–52.
Palermo T, Eccleston C, Lewandowski A, Williams A, Morley S. Randomized controlled trial of psychological therapies for management of chronic pain in children and adolescents: an updated meta-analytic review. Pain. 2010;148(3):387–97.
Hamaleinen M, Hoppu K, Valkeila E, Santavuori P. Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled crossover study. Neurology. 1997;48:103–7.
Hamaleinen M, Jones M, Loftus J, Saiers J. Sumatriptan nasal spray for migraine: a review of studies in patients aged 17 years and younger. Int J Clin Pract. 2002;56:704–9.
Weydert J, Ball T, Davis M. Systematic review of treatments for recurrent abdominal pain. Pediatrics. 2003;111:1–11.
Howard R. Chronic pain problems in children and young people. Contin Educ Anesth Crit Care Pain. 2011;11:219–23.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Appendix
Appendix
Sickle cell disease (SCD) fact sheet | |
---|---|
Definition | Healthy newborn infants are born with fetal hemoglobin (HbF), which transitions to normal adult hemoglobin (HbA) within 6 months of life. Sickle cell disease (SCD) is a group of blood disorders characterized by the presence of hemoglobin S (HbS) instead of normal HbA due to a point mutation in the hemoglobin β(beta)-globin chain gene. Disease classification depends upon the specific combinations of abnormal hemoglobin present: • The most severe forms of SCD are HbSS (sickle mutation in both β[beta]-globin genes) and HbSβ(beta)0thalassemia (sickle mutation in one gene and absent production of HbA in the other gene) • These are also referred to as “sickle cell anemia” • Less severe forms of SCD include HbSC (sickle mutation in 1 gene and another mutation causing abnormal hemoglobin in the other gene) and HbSβ(beta)+thalassemia (sickle mutation in 1 gene and underproduction of HbA in the other gene) |
Prevalence | SCD disproportionately affects individuals of African or Mediterranean descent, approximately 1 in 2474 live births in US • It can be found, however, in Hispanic and Caucasian populations • Demographic shifts affect local prevalence Survival rates into adulthood are increasing |
Pathophysiology | Disease manifestations are results of polymerization of abnormal red blood cell (RBC) hemoglobin in low oxygen states • Leads to deformation (“sickling”) of RBC • Can lead to RBC membrane deformation and vascular wall adhesion even when not sickled • Leads to fragility and decreased RBC lifespan, chronic hemolytic anemia of varying severity • Continuous cascade of inflammation, activation of white blood cells, platelets, and endothelial cells through complex biochemical processes affect microvascular blood flow • End organ damage results |
Symptoms | Individuals are at heightened risk for important chronic conditions as they age, including: • Chronic pain syndromes, acute or chronic pain episodes • Pulmonary hypertension • Chronic renal disease, hypertension, proteinuria • Strokes, silent cerebral infarctions affecting brain function • Proliferative sickle retinopathy, visual loss • Functional asplenia • Iron overload in organs if receiving chronic transfusion therapy |
Challenges in transition | The transition from pediatric to adult phase of life is known to be associated with increased SCD complications The use of beneficial therapies to manage SCD complications may also be underutilized in affected adults Many adult health care providers, especially primary care providers, are unfamiliar with the care of those living with SCD. Stigma and lack of trust are key issues when chronic pain is involved |
Helpful resources | • Sickle Cell Disease Association of America (resources for patients and family members, may include local chapters in communities throughout the US): http://www.sicklecelldisease.org • Sickle Cell Adult Provider Network (resources for health care providers, includes links to connect with SCD experts): • National Heart, Lung and Blood Institute Sickle Cell Disease Guidelines (developed by expert panel): http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines |
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Overholser, L.S., Diers, T., Hassell, K. (2016). Sickle Cell Disease. In: Pilapil, M., DeLaet, D., Kuo, A., Peacock, C., Sharma, N. (eds) Care of Adults with Chronic Childhood Conditions. Springer, Cham. https://doi.org/10.1007/978-3-319-43827-6_16
Download citation
DOI: https://doi.org/10.1007/978-3-319-43827-6_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-43825-2
Online ISBN: 978-3-319-43827-6
eBook Packages: MedicineMedicine (R0)